In this small cohort, sensitivity to ACh in female arteries still showed a trend to be better than in male arteries (females: 27.6 nM [range: 17.2-144nM] vs males: 136 nM [range: 44.8-351 nM]; P = 0.06) ( Supplemental Figure 1B ), whereas E max and precontraction levels were similar between sexes ( Supplemental Figures 1C and 1D ).
Another cyclin gene, CCNE1 also showed a trend for higher amplification frequency in ELF3/HNF4A up-regulated cancers (Student’s t -test p = 0.06).
The high-affinity receptor for BDNF, TrkB, showed a trend to elevation in PBT2-treated Tg2576 mice (+91%, p = 0.06).
The main effect of SWITCH showed a trend, F (1,19) = 4.07, p = 0.06, and interacted with prevGO, F (1,19) = 4.83, p = 0.03.
A high tumor OPN protein level was significantly related to tumor grade (p = 0.003) and an increased rate of relapse (p = 0.02), and also showed a trend association with high tumor stage (p = 0.06) (Table 3 ).
The A allele of rs1447295 was significantly associated with the risk of sporadic prostate cancer ( p = 0.04; age-adjusted OR, 1.34), while the G allele of rs6983267 showed a trend towards being a high-risk allele ( p = 0.06; age-adjusted OR, 1.27).
Finally, global protein synthesis as assessed via puromycin increased significantly with IGF-1 treatment ( p <0.0001) and showed a trend for an effect of CBD ( p =0.06) but no interaction effect ( p =0.18).
The same ANOVA showed a trend of difference in sensory recovery rate between the two groups (F=4.0, p =0.06).
The Hamilton Depression Rating Scale showed a trend toward reduction between the two evaluations ( p = 0.06; Table 3 ).
sXBP1 and CHOP showed a trend toward reduction with p values approaching statistical significance (p = 0.06).
Transfusion requirements for packed red cells were not different between the groups (ADR: 250 ± 322 ml; MIL: 204 ± 245 ml; CON: 87 ± 167 ml), whereas requirements for fresh frozen plasma showed a trend ( p = 0.06) for a higher use in the ADR and MIL groups (ADR: 107 ± 196 ml; MIL: 68 ± 161 ml; CON: 0 ± 0 ml).
No significant differences were observed among groups in glucose area under the curve (AUC) values, although the H group showed a trend versus control (p = 0.06).
In contrast, monoclonal antibody users did not experience a statistical difference (HR: 0.90; 95% CI: 0.76–1.05, p = 0.145), and notably, those using small molecule TKIs showed a trend toward increased risk with GLP1RA (HR: 1.23; 95% CI: 0.99–1.52, p = 0.060), although this was not statistically significant.
In the analysis of severe OITIGER in the full cohort, the revised protocol was associated with a significantly lower hazard ratio, consistent with both reduced and delayed risk (HR 0.44; 95% CI: 0.22–0.88; p = 0.02) (Figure 2B ), and AEC > 600/μL showed a trend toward increased risk (HR 1.76; 95% CI: 0.97–3.19; p = 0.06).
visualization), run (1 and 2) and repetition (1 and 2) showed a trend for the main effect of condition [F 1, 18 = 4.0, p = .06 , η p 2 = 0.18], with a higher degree of spontaneous mind-wandering indicated during visualization than verbalization.
At 24 months, PFDI-20 showed a trend toward lower scores in the LLSHE group (38.0 [17.0–53.0] vs. 48.0 [34.2–59.0]; P = 0.060), as did PFIQ-7 (23.0 [4.0–40.0] vs. 30.0 [16.0–43.2]; P = 0.255), though neither reached statistical significance.
Additional SAMA treatment plus LABA treatment significantly improved the activity domain of SGRQ score (MD: −2.33, 95% CI: −4.15 to −.50, p = .01, I 2 = 0%) but only showed a trend of an increase in the impact domain (MD: −1.72, 95% CI: −3.49 to .06, p = .06, I 2 = 0%) and the symptom domain (MD: −3.37, 95% CI: −7.42 to .67, p = .10, I 2 = 65%).
Notably, PMS supplementation led to a significant reduction in serum COR levels ( p < 0.05) and showed a trend towards decreasing serum NE levels ( p = 0.06). 3.3.
However, G2a tumors showed a trend towards longer OS than G2b tumors (5-year OS rates 95.5% vs. 80.8%, p = 0.060).
Although insulin levels showed a trend toward reduction, the difference was not statistically significant ( p = 0.06).
The differences between the groups showed a trend at 6 months ( n = 10, p = 0.06), although no change was observed at 12 months ( n = 7, p = 0.35).
Patients with fatigue (grades ≥3) showed a trend towards reduced survival (breast cancer-specific survival: HR = 1.17; 95 % CI, 0.99–1.37; P = 0.06).
In response to conventional vitamin D therapy, participants who remained vitamin D deficient showed a trend towards an increased LF:HF ( p = 0.06), an increase not observed in subjects who achieved vitamin D levels within the insufficient and sufficient ranges ( p < 0.001 vs. deficient vitamin D group) ( Appendix Table A1 , Figure 3 ).
The group SP showed a trend to overexpress ANGPT1 at day 35 and VEGF at day 70, when compared to group TP ( p = 0.06; data included in Table S3 ).
S9 A) and the CD4+ T cells showed a trend (p = 0.06) for higher expression of TIGIT (Fig.